This active molecular also known as AC220 and AC010220, is developed as a new second-generation FLT3 inhibitor for Flt3(ITD/WT) with IC50 of 1.1 nM/4.2 nM, ten fold more selective for Flt3 than KIT, PDGFRα, PDGFRβ, RET, and CSF-1R. Now Quizartinib is in Phase-III clinical trials in Acute myeloid leukaemia.
Products > Drug Discovery > Inhibitor | Products > Drug Discovery > Inhibitor | Cancer | FLT3
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.